Argentina vs Republic of Korea: Share of adolescent girls vaccinated against human papillomavirus
Argentina
67.0%
in 2024
Republic of Korea
65.0%
in 2024
Argentina rank
36th
Republic of Korea rank
38th
Share of adolescent girls vaccinated against human papillomavirus over time
- Argentina
- Republic of Korea
How they compare
Argentina currently reports 67.0% against 65.0% in Republic of Korea, a difference of 2.0%.
The two have swapped places 2 times across 7 shared years of data; in 2018 it was Argentina ahead.
Argentina ranks 36th and Republic of Korea ranks 38th of 74 countries.
Across the 2 decades both report, Argentina averaged higher in 1 and Republic of Korea in 1.
Head to head by decade
| Decade | Argentina | Republic of Korea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 60.0% | 55.5% | 4.5% | Argentina |
| 2020s | 68.6% | 69.4% | 0.8% | Republic of Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of adolescent girls vaccinated against human papillomavirus, Argentina or Republic of Korea?
- Argentina, at 67.0% against 65.0% in Republic of Korea as of 2024.
- What is the difference in share of adolescent girls vaccinated against human papillomavirus between Argentina and Republic of Korea?
- 2.0%, with Argentina ahead.
- How many years of comparable data are there for Argentina and Republic of Korea?
- 7 years are reported by both, from 2018 to 2024.
- How do Argentina and Republic of Korea rank globally for share of adolescent girls vaccinated against human papillomavirus?
- Argentina ranks 36th and Republic of Korea ranks 38th of 74 countries.
- Where does this data come from?
- WHO & UNICEF (2025) – processed by Our World in Data, published as Share of adolescent girls vaccinated against human papillomavirus. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Share of fifteen-year-old girls who, between the ages of 9 and 14, received their last dose of the human papillomavirus vaccine.